<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACREM</journal-id><journal-title-group><journal-title>Asian Case Reports in Emergency Medicine</journal-title></journal-title-group><issn pub-type="epub">2328-0409</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACREM.2017.54009</article-id><article-id pub-id-type="publisher-id">ACREM-24885</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACREM20170400000_53475824.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  PiCCO监测指导脓毒性休克患者早期目标导向液体治疗的临床研究
  Clinical Study on PiCCO Monitoring in Guidance of Early Goal-Directed Fluid Therapy in Patients with Septic Shock
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>振菁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卢</surname><given-names>燕</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>孟飞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邢</surname><given-names>学宁</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>宁夏医科大学，宁夏 银川</addr-line></aff><aff id="aff4"><addr-line>宁夏银川博康医院，宁夏 银川</addr-line></aff><aff id="aff3"><addr-line>宁夏医科大学第二附属医院，宁夏 银川</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>xingxuening@126.com(邢学)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>05</month><year>2018</year></pub-date><volume>05</volume><issue>04</issue><fpage>43</fpage><lpage>51</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨脉搏指示连续心排血量(PiCCO)监测在脓毒性休克患者早期目标导向液体治疗(EGDT)中的应用价值。方法：选择2015年9月~2017年7月宁夏医科大学第二附属医院ICU收治的脓毒性休克患者60例，按随机数字表法分为两组：PiCCO组(30例)患者在PiCCO监测指导下进行EGDT，传统组(30例)患者在中心静脉压(CVP)监测下进行EGDT。记录所有患者治疗前序贯器官衰竭估计评分(SOFA)和急性生理学与慢性健康状况评分系统II(APACHE II)，以及治疗前的CVP、平均动脉压(MAP)、血乳酸(LAC)。观察治疗后6 h、24 h、72 h两组患者的CVP、MAP、LAC、每小时尿量、血管活性药物使用剂量、复苏液体量，比较两组患者机械通气时间、住ICU时间、液体复苏6 h达标率、28天病死率等预后指标。记录PiCCO组患者治疗前后四个时间点的PiCCO监测参数。结果：1) 两组患者的年龄、性别比例、治疗前的SOFA评分、APACHE II评分、CVP、MAP、LAC相比无明显差异(P &gt; 0.05)。2) 治疗后6 h、24 h的CVP、MAP、每小时尿量、复苏液体量，PiCCO组患者显著高于传统组(P &lt; 0.05)；PiCCO组患者治疗后6 h、24 h LAC较传统组明显降低(P &lt; 0.05)；治疗后6 h、24 h、72 h血管活性药物使用剂量(去甲肾上腺素)，PiCCO组患者显著低于传统组(P &lt; 0.05)。3) 与传统组相比，治疗后PiCCO组患者机械通气时间和住ICU时间显著缩短(P &lt; 0.05)；治疗后PiCCO组患者液体复苏6 h达标率显著高于传统组(P &lt; 0.05)；两组患者28天病死率相比无明显差异(P &gt; 0.05)。4) 与治疗前相比，PiCCO组患者治疗后6 h、24 h、72 h的心排指数(CI)、胸腔内血容积指数(ITBVI)、全心舒张末期容积指数(GEDVI)明显增大(P &lt; 0.05)，但治疗后6 h、24 h、72 h的每搏量变异(SVV)显著减小(P &lt; 0.05)；与治疗后6 h相比，治疗后72 h的SVV明显减小(P &lt; 0.05)。与治疗前相比，治疗后72 h的外周血管阻力指数(SVRI)明显增大(P &lt; 0.05)。治疗前后血管外肺水指数(EVLWI)无明显变化(P &gt; 0.05)。结论：PiCCO指导脓毒性休克患者的EGDT，能提高患者液体复苏6 h达标率的同时不增加肺水，减少患者机械通气时间及住ICU时间，但对患者远期病死率改善无明显影响。 Objective: To observe the application value of pulse indicator continuous cardiac output (PiCCO) monitoring in guidance of early goal-directed fluid therapy (EGDT) in patients with septic shock. Methods: 60 cases patients with septic shock in intensive care unit (ICU) of the second affiliated hospital of Ningxia Medical University from September 2015 to July 2017 were selected. All pa-tients were randomly divided into two groups: PiCCO group (30 cases) received PiCCO monitoring to guide EGDT, traditional group (30 cases) received central venous pressure (CVP) monitoring to guide EGDT. Sequential organ failure assessment (SOFA) scores and acute physiology and chronic health evaluation II (APACHE II) scores, CVP, mean arterial pressure (MAP), blood lactic acid (LAC) before treatment of all patients were recorded. CVP, MAP, LAC, urine volume per hour, vascular active drug dosage, amount of fluid resuscitation at 6 h, 24 h, 72 h after the treatment of patients in the two groups were observed. Prognostic indicators (duration of mechanical ventilation, ICU stay time, 6 h fluid resuscitation standard rate, 28-day case fatality rate) of patients in the two groups were compared. PiCCO monitoring parameters at the four time points before and after treatment of patients in PiCCO group were recorded. Results: 1) There were no significant differences in age, sex ratio, SOFA scores, APACHE II scores, CVP, MAP, LAC before treatment of patients in the two groups (P &gt; 0.05). 2) CVP, MAP, urine volume per hour, amount of fluid resuscitation at 6 h, 24 h after the treatment of patients in PiCCO group were obviously higher than traditional group (P &lt; 0.05); LAC at 6 h, 24 h after the treatment of patients in PiCCO group was obviously lower than traditional group (P &lt; 0.05); vascular active drug dosage (norepinephrine) at 6 h, 24 h, 72 h after the treatment of patients in PiCCO group was obviously lower than traditional group (P &lt; 0.05). 3) In comparison to traditional group, PiCCO group showed obviously shorter in duration of mechanical ventilation and ICU stay time (P &lt; 0.05); 6 h fluid resuscitation standard rate of patients in PiCCO group was obviously higher than traditional group (P &lt; 0.05); there was no significant difference in 28-day case fatality rate of patients in the two groups (P &gt; 0.05). 4) Compared with that before treatment, cardiac output index (CI), intrathoracic blood volume index (ITBVI), global end diastolic volume index (GEDVI) at 6 h, 24 h, 72 h after the treatment of patients in PiCCO group were significantly increasing (P &lt; 0.05) while stroke volume variation (SVV) at 6 h, 24 h, 72 h after the treatment was significantly decreasing (P &lt; 0.05); SVV at 72 h after the treatment was obviously smaller than that at 6 h after the treatment (P &lt; 0.05). Compared with that before the treatment, systemic vascular resistance index (SVRI) at 72 h after the treatment was signifi-cantly increasing (P &lt; 0.05). Extravascular lung water index (EVLWI) had no significant change before and after treatment (P &gt; 0.05). Conclusion: PiCCO monitoring guiding EGDT in patients with septic shock can increase 6 h fluid resuscitation standard rate while does not increase lung water, reduces duration of mechanical ventilation and ICU stay time, but it has no obvious effect on long-term case fatality rate of patients.
    
  
 
</p></abstract><kwd-group><kwd>脓毒性休克(Septic shock)，脉搏指示连续心排血量(PiCCO)，早期目标导向液体治疗(EGDT), Septic Shock</kwd><kwd> Pulse Indicating Continuous Cardiac Output (PiCCO)</kwd><kwd> Early Goal-Directed Fluid Therapy (EGDT)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>PiCCO监测指导脓毒性休克患者早期目标导向液体治疗的临床研究<sup> </sup></title><p>刘振菁<sup>1</sup>，卢燕<sup>2</sup>，李孟飞<sup>2</sup>，邢学宁<sup>3*</sup></p><p><sup>1</sup>宁夏医科大学，宁夏 银川</p><p><sup>2</sup>宁夏医科大学第二附属医院，宁夏 银川</p><p><sup>3</sup>宁夏银川博康医院，宁夏 银川</p><disp-formula id="hanspub.24885-formula6"><graphic xlink:href="//html.hanspub.org/file/1-2440058x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年1月20日；录用日期：2018年3月20日；发布日期：2018年5月16日</p><disp-formula id="hanspub.24885-formula7"><graphic xlink:href="//html.hanspub.org/file/1-2440058x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨脉搏指示连续心排血量(PiCCO)监测在脓毒性休克患者早期目标导向液体治疗(EGDT)中的应用价值。方法：选择2015年9月~2017年7月宁夏医科大学第二附属医院ICU收治的脓毒性休克患者60例，按随机数字表法分为两组：PiCCO组(30例)患者在PiCCO监测指导下进行EGDT，传统组(30例)患者在中心静脉压(CVP)监测下进行EGDT。记录所有患者治疗前序贯器官衰竭估计评分(SOFA)和急性生理学与慢性健康状况评分系统II(APACHE II)，以及治疗前的CVP、平均动脉压(MAP)、血乳酸(LAC)。观察治疗后6 h、24 h、72 h两组患者的CVP、MAP、LAC、每小时尿量、血管活性药物使用剂量、复苏液体量，比较两组患者机械通气时间、住ICU时间、液体复苏6 h达标率、28天病死率等预后指标。记录PiCCO组患者治疗前后四个时间点的PiCCO监测参数。结果：1) 两组患者的年龄、性别比例、治疗前的SOFA评分、APACHE II评分、CVP、MAP、LAC相比无明显差异(P &gt; 0.05)。2) 治疗后6 h、24 h的CVP、MAP、每小时尿量、复苏液体量，PiCCO组患者显著高于传统组(P &lt; 0.05)；PiCCO组患者治疗后6 h、24 h LAC较传统组明显降低(P &lt; 0.05)；治疗后6 h、24 h、72 h血管活性药物使用剂量(去甲肾上腺素)，PiCCO组患者显著低于传统组(P &lt; 0.05)。3) 与传统组相比，治疗后PiCCO组患者机械通气时间和住ICU时间显著缩短(P &lt; 0.05)；治疗后PiCCO组患者液体复苏6 h达标率显著高于传统组(P &lt; 0.05)；两组患者28天病死率相比无明显差异(P &gt; 0.05)。4) 与治疗前相比，PiCCO组患者治疗后6 h、24 h、72 h的心排指数(CI)、胸腔内血容积指数(ITBVI)、全心舒张末期容积指数(GEDVI)明显增大(P &lt; 0.05)，但治疗后6 h、24 h、72 h的每搏量变异(SVV)显著减小(P &lt; 0.05)；与治疗后6 h相比，治疗后72 h的SVV明显减小(P &lt; 0.05)。与治疗前相比，治疗后72 h的外周血管阻力指数(SVRI)明显增大(P &lt; 0.05)。治疗前后血管外肺水指数(EVLWI)无明显变化(P &gt; 0.05)。结论：PiCCO指导脓毒性休克患者的EGDT，能提高患者液体复苏6 h达标率的同时不增加肺水，减少患者机械通气时间及住ICU时间，但对患者远期病死率改善无明显影响。</p><p>关键词 :脓毒性休克(Septic shock)，脉搏指示连续心排血量(PiCCO)，早期目标导向液体治疗(EGDT)</p><disp-formula id="hanspub.24885-formula8"><graphic xlink:href="//html.hanspub.org/file/1-2440058x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2440058x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2440058x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>近年来PiCCO开始广泛运用于临床，有创监测得到多项血流动力学参数指导脓毒性休克(Septic shock)患者的液体治疗，是目前国内外该领域的研究重点 [<xref ref-type="bibr" rid="hanspub.24885-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.24885-ref2">2</xref>] 。PiCCO是脉搏轮廓连续心排血量与经肺热稀释心排血量监测技术的结合，改善了以心率(Heart rate, HR)、血压、尿量等基本生命体征变化评估患者血容量不够精准的现状。根据改良的Stewart-Hamilton公式可计算出CI、ITBVI、GEDVI等热稀释参数和SVV、SVRI等脉搏轮廓参数，获得血流动力学的动态变化数据，使液体复苏治疗过程精准化 [<xref ref-type="bibr" rid="hanspub.24885-ref3">3</xref>] 。脓毒症最新定义为机体对感染的反应失调而导致危及生命的器官功能障碍，脓毒性休克是指脓毒症合并出现严重的循环障碍和细胞代谢紊乱 [<xref ref-type="bibr" rid="hanspub.24885-ref4">4</xref>] 。临床表现为持续性低血压。肺循环障碍，则肺毛细血管通透性变大，肺水肿情况加重。PiCCO通过经肺热稀释技术可以得到EVLWI，是评估肺水肿程度的定量指标，观察动态变化较X线胸片较早，是当前床旁实时监测肺水情况有希望的指标 [<xref ref-type="bibr" rid="hanspub.24885-ref5">5</xref>] 。因此，本研究应用PiCCO监测技术指导ICU脓毒性休克患者EGDT，观察是否能更准确地指导患者的液体治疗；减少肺水的发生；使机械通气和住ICU时间变短；是否能提高脓毒性休克患者的救治成功率，降低病死率。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 研究对象</title><p>选择2015年9月-2017年7月宁夏医科大学第二附属医院ICU收治的脓毒性休克患者60例，年龄在25~68岁之间。病例的疾病类型为腹腔感染性休克25例，肺部感染性休克19例，泌尿系感染性休克5例，导管相关性感染性休克7例，颅内感染性休克4例。根据随机数字表法分成两组：PiCCO组(30例)和传统组(30例)。</p><sec id="s4_1_1"><title>2.1.1. 纳入标准</title><p>纳入患者符合中国严重脓毒症/脓毒症休克治疗指南(2014)的诊断标准：(1)存在明确的感染部位；(2)有全身炎症反应综合征(SIRS)：有以下 ≥ 2项指标：①体温 &gt; 38℃或 &lt; 36℃；②HR &gt; 90次/min；③呼吸频率 &gt; 20次/min或动脉血二氧化碳分压 &lt; 32 mmHg或机械通气；④白细胞计数 &gt; 12 &#215; 10<sup>9</sup>/L或 &lt; 4 &#215; 10<sup>9</sup>/L，或不成熟白细胞 &gt; 0.01；(3)收缩压 &lt; 90 mmHg，或较基础血压下降 &gt; 40 mmHg，或MAP &lt; 70 mmHg，且给予充分液体治疗1 h后血压仍低，或需药物支持治疗；(4)伴有组织灌注不足：血乳酸 &gt; 4 mmol/L、少尿、神志障碍；(5)血培养中微生物致病菌可能为阳性。</p><p>患者年龄在18~75岁之间。APACHEⅡ ≥ 12分，进行机械通气。</p></sec><sec id="s4_1_2"><title>2.1.2. 排除标准</title><p>1) 年龄 &lt; 18岁或 &gt; 75 岁的患者；2) 急性心肌梗死患者；3) 肿瘤晚期患者；4) 临终状态难以治愈患者；5) 严重颅脑损伤患者；6) 存在锁骨下静脉或股动脉穿刺置管禁忌症的患者。</p></sec><sec id="s4_1_3"><title>2.1.3. 剔除标准</title><p>1) 其他原因导致的休克患者；2) 入院时间 &lt; 24 h的患者；3) 入组72 h内死亡的患者；4) 拒绝签署相关知晓同意书的患者。</p></sec></sec><sec id="s4_2"><title>2.2. 研究方法</title><sec id="s4_2_1"><title>2.2.1. 基本处理</title><p>所有患者入选后立即监测HR、血压等生命体征，进行血常规、生化常规、动脉血气分析、肝肾功能等检查，并准确测量每小时尿量。行APACHEⅡ评分，总分范围为0~71分，得分越高代表患者的病情越严重。通过SOFA评分对患者的呼吸、凝血、肝、循环、神经及肾脏六个系统评估，总分范围为0~43分，分数越高，表示预后越不好。所有患者按中国严重脓毒症/脓毒症休克治疗指南(2014)治疗，除给予液体复苏外，根据病情进行综合性治疗：识别脓毒性休克后1 h内给予广谱抗生素抗感染；调节电解质和酸碱平衡、利尿等对症治疗；给予适宜的营养支持治疗。所有患者行气管插管接呼吸机，设置合适的呼吸参数，选择同步间歇指令通气模式(synchronized intermittent mandatory ventilation, SIMV)：自主呼吸与间歇正压通气有机结合，保证病人的有效通气，又避免人机对抗。</p></sec><sec id="s4_2_2"><title>2.2.2. 锁骨下静脉穿刺置管</title><p>所有患者行锁骨下静脉穿刺置管术，置入中心静脉导管(双腔)，导管一腔连三通，与压力传感器连接后接监护仪，归零监测CVP。PiCCO组患者另一腔接注射液温度探头容纳管(T型管)，与注射液温度探头电缆连接后接PiCCO监护仪模块。</p></sec><sec id="s4_2_3"><title>2.2.3. 股动脉穿刺置管术</title><p>PiCCO组患者行股动脉穿刺置管术，置入热稀释导管，导管的压力端与动脉压力传感器连接后与监护仪相连，归零后监测动脉压。导管的温度热稀释端和PiCCO监护仪模块相连。行心输出量(Cardiac output, CO)的测量，基线平稳后从中心静脉导管温度探头端快速把20 ml的4℃的盐水打入，重复测量三次，取有效测量的平均值。记录监测的数据CI、ITBVI、GEDVI、EVLWI、SVRI和SVV等。</p></sec><sec id="s4_2_4"><title>2.2.4. 补液方法</title><p>传统组(n = 30)：以CVP指导补液治疗。CVP &lt; 8 mmHg时给予积极的补液治疗；CVP &gt; 12 mmHg时则限制液体的输注，同时应用利尿剂。根据MAP调整去甲肾上腺素的使用时机和使用剂量。6小时的治疗目标为：CVP在8~12 mmHg之间；MAP ≥ 65 mmHg；尿量 ≥ 0.5 mL∙kg<sup>−1</sup>∙h<sup>−1</sup>。</p><p>PiCCO组(n = 30)：根据PiCCO得到的监测指标指导补液治疗。EVLWI &lt; 3 mL/kg，GEDVI &lt; 680 mL/m<sup>2</sup>和(或)ITBVI &lt; 850 mL/m<sup>2</sup>时，进行积极的补液治疗；EVLWI &lt; 7 mL/kg，而GEDVI &gt; 800 mL/m<sup>2</sup>和(或)ITBVI &gt; 1000 mL/m<sup>2</sup>时，限制液体的输入；EVLWI &gt; 7 mL/kg时，限液的同时给予利尿剂进行脱水治疗。根据CI的监测值调整多巴酚丁胺等的使用时机和使用剂量；根据SVRI的监测值调整去甲肾上腺素的使用时机和使用剂量。6小时的治疗目标为：CI &gt; 3.0 L∙min<sup>−1</sup>∙m<sup>−2</sup>；GEDVI维持在680~800 mL/m<sup>2</sup>和(或)ITBVI维持在850~1000 mL/m<sup>2</sup>；EVLWI &lt; 7 mL/kg；MAP ≥ 65 mmHg；尿量 ≥ 0.5 mL∙kg<sup>−1</sup>∙h<sup>−1</sup>。</p></sec></sec><sec id="s4_3"><title>2.3. 观察指标</title><p>观察比较两组患者治疗前SOFA评分、APACHE II评分，治疗前及治疗后6 h、24 h和72 h的CVP、MAP、LAC，治疗后6 h、24 h和72 h的每小时尿量、去甲肾上腺素使用剂量和复苏液体量，以及治疗的效果：机械通气时间、住ICU时间、液体复苏6 h达标率、28天病死率。观察PiCCO组患者治疗前及治疗后6 h、24 h和72 h的CI、ITBVI、GEDVI、EVLWI、SVRI、SVV等血流动力学指标。</p></sec><sec id="s4_4"><title>2.4. 统计学分析</title><p>应用SPSS17.0统计软件处理数据。计量资料以均数 &#177; 标准差( x &#175; &#177; s )表示，组间比较采用独立样本t检验，组内比较采用重复测量数据的方差分析；计数资料以构成比或百分比表示，组间比较采用c<sup>2</sup>检验。以 P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 两组一般情况的比较</title><p>两组患者的年龄、性别构成比、治疗前的SOFA评分、APACHE II评分、CVP、MAP、LAC相比无明显差异(P &gt; 0.05)。见表1。</p></sec><sec id="s5_2"><title>3.2. 两组液体复苏后不同时间点相关指标的比较</title><p>治疗后6 h、24 h的CVP、MAP、每小时尿量、复苏液体量，PiCCO组患者高于传统组(P &lt; 0.05)；PiCCO组患者治疗后6 h、24 h LAC较传统组降低(P &lt; 0.05)；治疗后6 h、24 h、72 h去甲肾上腺素的使用剂量PiCCO组患者低于传统组(P &lt; 0.05)。见表2。</p></sec><sec id="s5_3"><title>3.3. 两组治疗效果的比较</title><p>与传统组比较，PiCCO组患者机械通气时间和住ICU时间缩短(P &lt; 0.05)；治疗后PiCCO组患者液体复苏6 h达标率高于传统组(P &lt; 0.05)；两组患者28天病死率比较无明显差异(P &gt; 0.05)。见表3。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The comparison of general conditions between the two groups (n = 30, x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >年龄</th><th align="center" valign="middle" >性别构成比 (男/女)</th><th align="center" valign="middle" >SOFA评分</th><th align="center" valign="middle" >APACHE II评分</th><th align="center" valign="middle" >CVP (mmHg)</th><th align="center" valign="middle" >MAP (mmHg)</th><th align="center" valign="middle" >LAC (mmol/L)</th></tr></thead><tr><td align="center" valign="middle" >PiCCO组</td><td align="center" valign="middle" >56 &#177; 9.5</td><td align="center" valign="middle" >20/10</td><td align="center" valign="middle" >16 &#177; 3.6</td><td align="center" valign="middle" >26 &#177; 4.5</td><td align="center" valign="middle" >4.4 &#177; 1.6</td><td align="center" valign="middle" >50 &#177; 4.4</td><td align="center" valign="middle" >7.3 &#177; 3.6</td></tr><tr><td align="center" valign="middle" >传统组</td><td align="center" valign="middle" >54 &#177; 10.1</td><td align="center" valign="middle" >19/11</td><td align="center" valign="middle" >17 &#177; 3.1</td><td align="center" valign="middle" >26 &#177; 5.8</td><td align="center" valign="middle" >4.5 &#177; 1.7</td><td align="center" valign="middle" >50 &#177; 5.2</td><td align="center" valign="middle" >7.8 &#177; 3.1</td></tr><tr><td align="center" valign="middle" >t(c<sup>2</sup>)</td><td align="center" valign="middle" >0.39</td><td align="center" valign="middle" >0.45</td><td align="center" valign="middle" >0.73</td><td align="center" valign="middle" >1.14</td><td align="center" valign="middle" >0.39</td><td align="center" valign="middle" >0.34</td><td align="center" valign="middle" >0.35</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&gt;0.05</td></tr></tbody></table></table-wrap><p>表1. 两组患者一般情况的比较(n = 30,<inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2440058x12_hanspub.png" xlink:type="simple"/></inline-formula>)</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The comparison of related parameters in different time points after fluid resuscitation between the two groups (n = 30, x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >治疗时间(h)</th><th align="center" valign="middle" >CVP (mmHg)</th><th align="center" valign="middle" >MAP (mmHg)</th><th align="center" valign="middle" >LAC (mmol/L)</th><th align="center" valign="middle" >尿量 (mL∙kg<sup>−1</sup>∙h<sup>−1</sup>)</th><th align="center" valign="middle" >去甲肾上腺素 (ug∙kg<sup>−1</sup>∙min<sup>−1</sup>)</th><th align="center" valign="middle" >复苏液体量 (mL)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >PiCCO组</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.3 &#177; 2.7<sup>*</sup></td><td align="center" valign="middle" >70 &#177; 7.6<sup>*</sup></td><td align="center" valign="middle" >3.0 &#177; 1.5<sup>*</sup></td><td align="center" valign="middle" >0.68 &#177; 0.18<sup>*</sup></td><td align="center" valign="middle" >0.42 &#177; 0.26<sup>*</sup></td><td align="center" valign="middle" >3080 &#177; 232<sup>*</sup></td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >8.8 &#177; 3.1<sup>*</sup></td><td align="center" valign="middle" >73 &#177; 6.5<sup>*</sup></td><td align="center" valign="middle" >2.2 &#177; 1.8<sup>*</sup></td><td align="center" valign="middle" >0.96 &#177; 0.23<sup>*</sup></td><td align="center" valign="middle" >0.32 &#177; 0.18<sup>*</sup></td><td align="center" valign="middle" >6170 &#177; 446<sup>*</sup></td></tr><tr><td align="center" valign="middle" >72</td><td align="center" valign="middle" >10.5 &#177; 2.8</td><td align="center" valign="middle" >79 &#177; 9.2</td><td align="center" valign="middle" >1.6 &#177; 0.5</td><td align="center" valign="middle" >1.09 &#177; 0.17</td><td align="center" valign="middle" >0.12 &#177; 0.15<sup>*</sup></td><td align="center" valign="middle" >13460 &#177; 1312</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >传统组</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6.2 &#177; 2.0</td><td align="center" valign="middle" >60 &#177; 9.3</td><td align="center" valign="middle" >4.0 &#177; 0.9</td><td align="center" valign="middle" >0.51 &#177; 0.15</td><td align="center" valign="middle" >0.55 &#177; 0.19</td><td align="center" valign="middle" >2090 &#177; 198</td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >7.4 &#177; 2.5</td><td align="center" valign="middle" >66 &#177; 8.9</td><td align="center" valign="middle" >3.3 &#177; 1.0</td><td align="center" valign="middle" >0.68 &#177; 0.16</td><td align="center" valign="middle" >0.45 &#177; 0.13</td><td align="center" valign="middle" >5270 &#177; 402</td></tr><tr><td align="center" valign="middle" >72</td><td align="center" valign="middle" >10.0 &#177; 4.8</td><td align="center" valign="middle" >76 &#177; 8.5</td><td align="center" valign="middle" >1.7 &#177; 0.3</td><td align="center" valign="middle" >1.13 &#177; 0.24</td><td align="center" valign="middle" >0.24 &#177; 0.21</td><td align="center" valign="middle" >13350 &#177; 1288</td></tr></tbody></table></table-wrap><p>表2. 两组液体复苏后不同时间点相关指标的比较(n = 30, x &#175; &#177; s )</p><p>注：与传统组比较：*P &lt; 0.05。</p></sec><sec id="s5_4"><title>3.4. PiCCO组内不同时间点PiCCO监测指标的比较</title><p>与治疗前比较，治疗后6 h、24 h、72 h的CI、ITBVI、GEDVI明显增大但治疗后6 h、24 h、72 h的SVV减小(P &lt; 0.05)；与治疗后6 h比较，治疗后72 h的SVV明显减小(P &lt; 0.05)。与治疗前比较，治疗后72 h的SVRI增大(P &lt; 0.05)。治疗前后EVLWI无明显变化(P &gt; 0.05)。见表4。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>脓毒症是由于微生物的感染引起，新概念强调以机体对感染的反应失调和器官功能障碍为核心。机体反应失调本质是细胞层面的生理及生化异常以全身炎症反应综合征(Systemic inflammatory response syndrome, SIRS)的发生为早期表现。脓毒性休克是指脓毒症合并出现严重的循环障碍和细胞代谢紊乱，临床表现为多器官功能障碍或者循环功能障碍，特点是持续性低血压，本研究两组患者治疗前MAP、CVP均较低，充分容量复苏后仍需血管收缩药维持血压，当危及生命的器官功能障碍发生，死亡风险升高，是人类死亡的十大因素之一，其死亡率接近与心肌梗死导致的死亡，位居死亡因素第5位 [<xref ref-type="bibr" rid="hanspub.24885-ref6">6</xref>] 。</p><p>脓毒性休克的发病受到多个因素的共同作用，目前普遍认为内毒素是该病的启动因素 [<xref ref-type="bibr" rid="hanspub.24885-ref7">7</xref>] 。由于微生物及各种毒素的作用使脓毒症患者机体产生大量细胞因子，导致机体反应失调。血管通透性变大，外周血管内大量液体渗出至血管外组织间隙和第三间隙 [<xref ref-type="bibr" rid="hanspub.24885-ref8">8</xref>] ；毒素物质也可直接导致外周血管的扩张；另外，毒素物质还会对患者心肌细胞造成损害，使心脏射血能力下降 [<xref ref-type="bibr" rid="hanspub.24885-ref9">9</xref>] 。以上三个方面共同作用使脓毒症患者外周血容量明显减少，循环发生障碍，毛细血管内的血液处于低灌注、停滞或者瘀滞状态，机体微循环发生缺血缺氧，组织进行无氧代谢，乳酸生成增加 [<xref ref-type="bibr" rid="hanspub.24885-ref10">10</xref>] 。本研究两组患者治疗前LAC的浓度均明显增高：PiCCO组增高至7.3 &#177; 3.6 mmol/L；传统组增高至7.8 &#177; 3.1 mmol/L。血管张力降低使外周循环阻力下降，</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The comparison of treatment effect between the two groups [ n = 30, x &#175; &#177; s , n (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >机械通气时间(h)</th><th align="center" valign="middle" >住ICU时间(d)</th><th align="center" valign="middle" >液体复苏6 h达标率(%)</th><th align="center" valign="middle" >28天病死率(%)</th></tr></thead><tr><td align="center" valign="middle" >PiCCO组</td><td align="center" valign="middle" >136 &#177; 64</td><td align="center" valign="middle" >12 &#177; 3.6</td><td align="center" valign="middle" >23(76.7)</td><td align="center" valign="middle" >7(23.3)</td></tr><tr><td align="center" valign="middle" >传统组</td><td align="center" valign="middle" >155 &#177; 71</td><td align="center" valign="middle" >17 &#177; 7.1</td><td align="center" valign="middle" >17(56.7)</td><td align="center" valign="middle" >8(26.7)</td></tr><tr><td align="center" valign="middle" >t或c<sup>2</sup></td><td align="center" valign="middle" >2.47</td><td align="center" valign="middle" >2.28</td><td align="center" valign="middle" >4.38</td><td align="center" valign="middle" >0.41</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&gt;0.05</td></tr></tbody></table></table-wrap><p>表3. 两组治疗效果的比较[ n = 30, x &#175; &#177; s , n (%)]</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The comparison of PiCCO monitoring indicators in different time points in PiCCO group ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后6 h</th><th align="center" valign="middle" >治疗后24 h</th><th align="center" valign="middle" >治疗后72 h</th></tr></thead><tr><td align="center" valign="middle" >CI (L∙min<sup>−1</sup>∙m<sup>−2</sup>)</td><td align="center" valign="middle" >1.7 &#177; 0.98</td><td align="center" valign="middle" >3.9 &#177; 0.81<sup>▲</sup></td><td align="center" valign="middle" >3.8 &#177; 1.03<sup>▲</sup></td><td align="center" valign="middle" >4.5 &#177; 0.82<sup>▲</sup></td></tr><tr><td align="center" valign="middle" >ITBVI (mL/m<sup>2</sup>)</td><td align="center" valign="middle" >518 &#177; 155</td><td align="center" valign="middle" >861 &#177; 173<sup>▲</sup></td><td align="center" valign="middle" >890 &#177; 168<sup>▲</sup></td><td align="center" valign="middle" >927 &#177; 192<sup>▲</sup></td></tr><tr><td align="center" valign="middle" >GEDVI (mL/m<sup>2</sup>)</td><td align="center" valign="middle" >451 &#177; 203</td><td align="center" valign="middle" >651 &#177; 225<sup>▲</sup></td><td align="center" valign="middle" >734 &#177; 176<sup>▲</sup></td><td align="center" valign="middle" >781 &#177; 104<sup>▲</sup></td></tr><tr><td align="center" valign="middle" >EVLWI (mL/kg)</td><td align="center" valign="middle" >6.2 &#177; 1.43</td><td align="center" valign="middle" >5.7 &#177; 1.09</td><td align="center" valign="middle" >5.5 &#177; 2.37</td><td align="center" valign="middle" >4.9 &#177; 1.52</td></tr><tr><td align="center" valign="middle" >SVRI (dyn∙s&#183;m<sup>2</sup>∙cm<sup>−5</sup>)</td><td align="center" valign="middle" >831 &#177; 105</td><td align="center" valign="middle" >1107 &#177; 184</td><td align="center" valign="middle" >1138 &#177; 173</td><td align="center" valign="middle" >1809 &#177; 154<sup>▲</sup></td></tr><tr><td align="center" valign="middle" >SVV(%)</td><td align="center" valign="middle" >21 &#177; 1.9</td><td align="center" valign="middle" >15 &#177; 3.7<sup>▲</sup></td><td align="center" valign="middle" >12 &#177; 1.7<sup>▲</sup></td><td align="center" valign="middle" >8 &#177; 1.8<sup>▲■</sup></td></tr></tbody></table></table-wrap><p>表4. PiCCO组内不同时间点PiCCO监测指标的比较( x &#175; &#177; s )</p><p>注：与治疗前相比，<sup>▲</sup>P &lt; 0.05；与治疗后6 h相比，<sup>■</sup>P &lt; 0.05。</p><p>患者出现顽固性低血压。Standage等人认为外周循环阻力的下降是脓毒性休克最早表现出来的血流动力学变化，其变化的幅度和患者病情及预后关系密切 [<xref ref-type="bibr" rid="hanspub.24885-ref11">11</xref>] 。通过SVRI能良好地观察患者外周循环阻力的变化情况，指导血管活性药物的使用 [<xref ref-type="bibr" rid="hanspub.24885-ref12">12</xref>] 。本文PiCCO组患者治疗前SVRI为831 &#177; 105 dyn∙s∙m<sup>2</sup>∙cm<sup>−5</sup>，明显低于正常值(1200-2000 dyn&#183;s&#183;m<sup>2</sup>&#183;cm<sup>-5</sup>)的下限，说明患者治疗前外周血管处于麻痹状态，应用血管活性药物(去甲肾上腺素)后，PiCCO组患者SVRI逐渐改善，治疗后72 h后恢复至正常范围，与治疗前相比明显增大(P &lt; 0.05)。根据SVRI值指导患者血管活性药物(去甲肾上腺素)的使用情况，PiCCO组治疗后6 h、24 h、72 h去甲肾上腺的使用量较传统组明显减少(P &lt; 0.05)，说明SVRI指导血管活性药物的使用更精确，能避免药物使用过量。</p><p>脓毒性休克患者进行EGDT时，传统监测指标有CVP、肺动脉锲压(pulmonary artery wedge pressure, PAWP)等，但EGDT的依从性以及其6 h达标率明显较低。究其原因可能与以下几点有关 [<xref ref-type="bibr" rid="hanspub.24885-ref13">13</xref>] ：(1)CVP、PAWP均是压力指标，以压力指标代表容量，准确性较差。(2)干扰CVP、PAWP的因素较多：①脓毒性休克的患者心肌常受到毒素的侵害，顺应性下降，引起CVP、PAWP的改变。②肺部、胸部、腹部的损伤使胸腔内压力增大，以及机械通气均会引起CVP、PAWP监测偏差。</p><p>PiCCO用于脓毒性休克患者的液体治疗，能连续监测包括CVP、MAP、CI、SVRI、SVV、ITBVI、GEDVI、EVLWI等多个血流动力学参数。研究表明ITBVI是一个敏感、可重复评估患者心脏前负荷的指标，其与CI的相关性明显优于CVP。ITBVI联合GEDVI能更好地评估患者SVV的变化，使补液的容量及速度更精准 [<xref ref-type="bibr" rid="hanspub.24885-ref14">14</xref>] 。脓毒性休克患者血管通透性增加，常引起肺水的形成。临床上常通过X线检查等评估患者肺部情况，但其与患者肺水肿的敏感性较差。当EVLWI增加超过2倍时，在胸片上才能表现出来。EVLWI的测定不受血管通透性的干扰，是目前测量患者肺水肿的比较好的指标，能量化肺水肿程度，还能克服了胸片受肌肉、脂肪、气体等因素的影响 [<xref ref-type="bibr" rid="hanspub.24885-ref15">15</xref>] 。</p><p>本研究两组患者均行机械通气，PiCCO组患者通过PiCCO监测指导EGDT，根据CI、ITBVI、GEDVI、EVLWI、SVRI、SVV等血流动力学指标的变化，及时调整液体、血管活性药物、利尿剂等使用情况。PiCCO组患者组内比较时，与治疗前比，治疗后6 h、24 h、72 h的CI、ITBVI、GEDVI明显增大但治疗后6 h、24 h、72 h的SVV显著减小(P &lt; 0.05)；说明PiCCO指导进行EGDT，能使患者的血容量逐渐增加，心肌功能恢复，心排指数增加至正常水平。与传统组相比，治疗后6 h、24 h的CVP、MAP、每小时尿量、复苏液体总量，PiCCO组明显增高(P &lt; 0.05)，说明在PiCCO各指标的指导下调节液体的复苏，临床效果更好。治疗后PiCCO组液体复苏6 h达标率远大于传统组(P &lt; 0.05)，且治疗后6 h、24 h、72 h血管活性药物使用剂量(去甲肾上腺素)明显低于传统组(P &lt; 0.05)，说明PiCCO组不是单纯依靠血管药物增加患者的MAP，而是综合患者循环情况，调节液体、血管活性药物等的使用，最终使液体复苏6 h达标率提高。与传统组相比，PiCCO组治疗后6 h、24 h后LAC的水平也显著降低(P &lt; 0.05)，说明PiCCO指导EGDT，能及时纠正患者的分布性休克，增加组织血液灌注，减少组织缺血缺氧，减少血乳酸的生成。另外，PiCCO组内比较时，治疗前后EVLWI无明显变化(P &gt; 0.05)，说明PiCCO指导EGDT，改善患者液体情况的同时不增加肺水肿的发生。最终PiCCO组机械通气时间和住ICU时间较传统组显著缩短(P &lt; 0.05)，与以往的研究相一致 [<xref ref-type="bibr" rid="hanspub.24885-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.24885-ref17">17</xref>] 。但由于脓毒性休克患者一般病情复杂，机体对感染的反应有明显差异，器官功能障碍和合并症较多，容量复苏是综合救治的前提，液体治疗对于患者远期转归的影响尚不明确。本研究两组患者28天的病死率比较无明显差异(P &gt; 0.05)，与三个大型随机试验结果相似 [<xref ref-type="bibr" rid="hanspub.24885-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.24885-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.24885-ref20">20</xref>] ，说明无论是在PiCCO还是在传统监测指标下，单纯的EGDT和容量复苏并不能显著减少脓毒性休克患者的病死率，对于该类患者更多的系统性和精准性治疗是提高远期生存的关键。</p></sec><sec id="s7"><title>5. 研究的局限性</title><p>本文未能对所有患者的胸部X片或CT进行统计分析，仅根据患者的CVP、MAP、ITBVI、GEDVI等指标评估患者治疗前后肺水变化情况不够全面。</p></sec><sec id="s8"><title>6. 结论</title><p>1) PiCCO监测指导脓毒性休克患者的EGDT，优于传统的CVP监测治疗。提高患者液体复苏6 h达标率的同时不增加肺水，缩短机械通气时间和住ICU时间。</p><p>2) PiCCO监测指导脓毒性休克患者的EGDT，对患者远期病死率无明显改善。</p></sec><sec id="s9"><title>文章引用</title><p>刘振菁,卢燕,李孟飞,邢学宁. PiCCO监测指导脓毒性休克患者早期目标导向液体治疗的临床研究 Clinical Study on PiCCO Monitoring in Guidance of Early Goal-Directed Fluid Therapy in Patients with Septic Shock[J]. 亚洲急诊医学病例研究, 2017, 05(04): 43-51. https://doi.org/10.12677/ACREM.2017.54009</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24885-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Gassanov, N., Caglayan, E., Nia, A., et al. (2011) Hemodynamic Monitoring in the Intensive Care Unit: Pulmonary Artery Catheter Versus PiCCO. Deutsche Medizinische Wochenschrift, 136, 376-380.  
&lt;br&gt;https://doi.org/10.1055/s-0031-1272539</mixed-citation></ref><ref id="hanspub.24885-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">伍义, 马月丹, 吴寿坤. PICCO容量性指标在感染性休克液体复苏中的临床应用[J]. 现代中西医结合杂志, 2013, 22(1): 16-17.</mixed-citation></ref><ref id="hanspub.24885-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Belda, F.J., Aguilar, G., Teboul, J.L., et al. (2011) Complications Related to Less-Invasive Haemodynamic Monitoring. British Journal of Anaesthesia, 106, 482-486. &lt;br&gt;https://doi.org/10.1093/bja/aeq377</mixed-citation></ref><ref id="hanspub.24885-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">薄禄龙, 卞金俊, 邓小明. 2016年脓毒症最新定义与诊断标准: 回归本质重新出发[J]. 中华麻醉学杂志, 2016, 36(3): 259-262.</mixed-citation></ref><ref id="hanspub.24885-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Jozwiak, M., Teboul, J.L. and Monnet, X. (2015) Extravascular Lung Water in Critical Care: Recent Advances and Clinical Applications. Annals of Intensive Care, 5, 38. &lt;br&gt;https://doi.org/10.1186/s13613-015-0081-9</mixed-citation></ref><ref id="hanspub.24885-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Jr, O.J., Lu, B., Ali, N.A., et al. (2011) Insurance Type and Sep-sis-Associated Hospitalizations and Sepsis-Associated Mortality among US Adults: A Retrospective Cohort Study. Critical Care, 15, R130. &lt;br&gt;https://doi.org/10.1186/cc10243</mixed-citation></ref><ref id="hanspub.24885-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Adamik, B., Zielinski, S., Smiechowicz, J., et al. (2015) Endotoxin Elimination in Patients with Septic Shock: An Observation Study. Archivum Immunologiae et Therapiae Experimentalis, 63, 475-483.  
&lt;br&gt;https://doi.org/10.1007/s00005-015-0348-8</mixed-citation></ref><ref id="hanspub.24885-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Mermutluoglu, C., Deveci, O., Dayan, S., et al. (2016) Antifungal Susceptibility and Risk Factors in Patients with Candidemia. Eurasian Journal of Medicine, 48, 199-203. &lt;br&gt;https://doi.org/10.5152/eurasianmed.2016.0021</mixed-citation></ref><ref id="hanspub.24885-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Fujishima, S. (2016) Organ Dysfunction as a New Standard for Defining Sepsis. Inflammation and Regeneration, 36, 24. &lt;br&gt;https://doi.org/10.1186/s41232-016-0029-y</mixed-citation></ref><ref id="hanspub.24885-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">包磊, 张敏, 颜培夏, 等. 动脉血乳酸及其清除率预测感染性休克患者预后的回顾性研究[J]. 中华危重症急救医学, 2015, 27(1): 38-42.</mixed-citation></ref><ref id="hanspub.24885-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Standage, S.W., Caldwell, C.C., Zingarelli, B., et al. (2012) Reduced PPARα Expression Is Associated with Decreased Survival and Increased Tissue Bacterial Load in Sepsis. Shock, 37, 164-169.  
&lt;br&gt;https://doi.org/10.1097/SHK.0b013e31823f1a00</mixed-citation></ref><ref id="hanspub.24885-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lee, E.P., Hsia, S.H., Lin, J.J., et al. (2017) Hemodynamic Analysis of Pediatric Septic Shock and Cardiogenic Shock Using Transpulmonary Thermodilution. BioMed Research International, 2017, 1-7.  
&lt;br&gt;https://doi.org/10.1155/2017/3613475</mixed-citation></ref><ref id="hanspub.24885-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Zhu, W., Tan, J., et al. (2017) Early Outcome of Early-Goal Directed Therapy for Patients with Sepsis or Septic Shock: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oncotarge, 8, 27510-27519.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.15550</mixed-citation></ref><ref id="hanspub.24885-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Tagami, T., Nakamura, T., Kushimoto, S., et al. (2014) Early-Phase Changes of Extravascular Lung Water Index as a Prognostic Indicator in Acute Respiratory Distress Syndrome Patients. Annals of Intensive Care, 4, 27.  
&lt;br&gt;https://doi.org/10.1186/s13613-014-0027-7</mixed-citation></ref><ref id="hanspub.24885-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Hao, W., Na, C., Su, L., et al. (2016) Prognostic Value of Extravascular Lung Water and Its Potential Role in Guiding Fluid Therapy in Septic Shock after Initial Resuscitation. Journal of Critical Care, 33, 106-113.  
&lt;br&gt;https://doi.org/10.1016/j.jcrc.2016.02.011</mixed-citation></ref><ref id="hanspub.24885-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Yuanbo, Z., Jin, W., Fei, S., et al. (2016) ICU Management Based on PiCCO Parameters Reduces Duration of Mechanical Ventilation and ICU Length of Stay in Patients with Severe Thoracic Trauma and Acute Respiratory Distress Syndrome. Annals of Intensive Care, 6, 113. &lt;br&gt;https://doi.org/10.1186/s13613-016-0217-6</mixed-citation></ref><ref id="hanspub.24885-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z., Xiao, X., Min, Y., et al. (2013) Use of the PiCCO System in Critically Ill Patients with Septic Shock and Acute Respiratory Distress Syndrome: A Study Protocol for a Randomized Controlled Trial. Trials, 14, 32.  
&lt;br&gt;https://doi.org/10.1186/1745-6215-14-32</mixed-citation></ref><ref id="hanspub.24885-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yealy, D.M., Kellum, J.A., Huang, D.T., et al. (2014) A Randomized Trial of Protocol-Based Care for Early Septic Shock. New England Journal of Medicine, 370, 1683-1693. &lt;br&gt;https://doi.org/10.1056/NEJMoa1401602</mixed-citation></ref><ref id="hanspub.24885-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Priebe, H.J. (2015) Early Goal-Directed Resuscitation for Septic Shock. N Engl J Med, 373, 1301-1311.</mixed-citation></ref><ref id="hanspub.24885-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Peake, S.L., Delaney, A., Bailey, M., et al. (2014) Goal-Directed Resuscitation for Patients with Early Septic Shock. New England Journal of Medicine, 371, 1496-1506. &lt;br&gt;https://doi.org/10.1056/NEJMoa1404380</mixed-citation></ref></ref-list></back></article>